Holen Sie sich die Stockscreener-App
22.63
0.09%
-0.02
Schlusskurs vom Vortag:
$22.65
Offen:
$22.5
24-Stunden-Volumen:
3.10M
Relative Volume:
1.29
Marktkapitalisierung:
$2.86B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-11.15
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-2.41%
1M Leistung:
-17.92%
6M Leistung:
+3.48%
1J Leistung:
-21.53%
1-Tages-Spanne:
$22.19
$22.99
1-Wochen-Bereich:
$21.07
$23.30
52-Wochen-Spanne:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
22.63 | 2.86B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals: Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders - Seeking Alpha
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS) - MSN
Volume spikes in Apellis Pharmaceuticals Inc. stock – what they meanJuly 2025 Intraday Action & Long-Term Investment Growth Plans - newser.com
What drives Apellis Pharmaceuticals Inc stock priceInstitutional Buying Trends & Free Exceptional Risk Adjusted Gains - earlytimes.in
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada
Apellis Pharmaceuticals CFO sells $16,119 in stock - MSN
Published on: 2025-09-29 15:38:29 - newser.com
What MACD and RSI say about Apellis Pharmaceuticals Inc.Weekly Earnings Recap & Low Drawdown Momentum Ideas - newser.com
Can Apellis Pharmaceuticals Inc. stock surprise with earnings upsideQuarterly Profit Review & AI Powered Market Entry Ideas - newser.com
Smart tools for monitoring Apellis Pharmaceuticals Inc.’s price actionJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Using R and stats models for Apellis Pharmaceuticals Inc. forecasting2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com
What Fibonacci levels say about Apellis Pharmaceuticals Inc. reboundQuarterly Earnings Summary & Reliable Price Breakout Signals - newser.com
Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by Wealth Enhancement Advisory Services LLC - MarketBeat
Why retail investors pile into Apellis Pharmaceuticals Inc. stockOptions Play & Scalable Portfolio Growth Ideas - newser.com
Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns By Investing.com - Investing.com Nigeria
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know - Benzinga
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) with Low - GuruFocus
Goldman Sachs Downgrades Apellis Pharmaceuticals (APLS) Amid Com - GuruFocus
Apellis down as Goldman Sachs cuts to sell on risks to outlook - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down After Analyst Downgrade - MarketBeat
Apellis stock cut to sell at Goldman Sachs (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by The Goldman Sachs Group - MarketBeat
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market SessionApellis Pharmaceuticals (NASDAQ:APLS), Concentrix (NASDAQ:CNXC) - Benzinga
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket - Benzinga
Goldman Sachs Downgrades Apellis Pharmaceuticals to Sell From Neutral, Adjusts PT to $18 From $26 - MarketScreener
Goldman Sachs downgrades Apellis stock to Sell on Syfovre growth concerns - Investing.com
Fierce Biotech Layoff Tracker 2025: IO lays off 50% of employees; Heidelberg reduces headcount by 75% - Fierce Biotech
Apellis Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Pallas Capital Advisors LLC Has $949,000 Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Director Sells $713,561.40 in Stock - MarketBeat
Zacks Research Has Bullish Estimate for APLS FY2025 Earnings - MarketBeat
How to monitor Apellis Pharmaceuticals Inc. with trend dashboardsMarket Volume Report & Fast Exit/Entry Strategy Plans - newser.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells $121,700.00 in Stock - MarketBeat
Setup Watch: Should I invest in ATMV before earningsTreasury Yields & Fast Moving Stock Watchlists - khodrobank.com
Dunlop A. Sinclair sells Apellis (APLS) shares worth $713k - Investing.com
Goldman Sachs Group Inc. Has $6.73 Million Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharma director Dunlop sells $713,561 in shares By Investing.com - Investing.com Canada
Apellis Pharma director Dunlop sells $713,561 in shares - Investing.com India
Dunlop A. Sinclair sells Apellis (APLS) shares worth $713k By Investing.com - Investing.com South Africa
Can volume confirm reversal in Apellis Pharmaceuticals Inc.Forecast Cut & Daily Technical Forecast Reports - newser.com
Evaluating Apellis Pharmaceuticals Inc. with trendline analysisJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Stock Market Recap: Will Apellis Pharmaceuticals Inc benefit from rising consumer demand2025 Market Outlook & AI Driven Price Predictions - خودرو بانک
Key resistance and support levels for Apellis Pharmaceuticals Inc.2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - newser.com
Best data tools to analyze Apellis Pharmaceuticals Inc. stockTrade Risk Assessment & Reliable Price Action Trade Plans - newser.com
What is the long term forecast for Apellis Pharmaceuticals Inc stock2025 Trading Recap & Fast Entry High Yield Tips - khodrobank.com
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):